Literature DB >> 24094504

[Bitemporal hemianopia as presenting sign of severe ethambutol toxicity].

E Boulanger Scemama1, V Touitou, P Le Hoang.   

Abstract

INTRODUCTION: Optic neuropathy is a severe and well-known complication of ethambutol treatment. If not detected early, it may lead to profound and irreversible vision loss. CASE REPORT: We report the case of a 83-year-old female patient, referred for rapidly progressive, painless, bilateral visual loss, unimproved after bilateral cataract surgery. Automated Humphrey 24-2 visual field demonstrated bitemporal hemianopia associated with bilateral central scotoma. Brain MRI did not demonstrate any compressive lesion in the chiasmal region. However, on T2-weighted sequences, an area of elevated signal intensity appeared within the optic chiasm, enhancing after gadolinium injection. On detailed history, it was noted that the patient had been on ethambutol for the last 18months, for the treatment of a Mycobacterium avium-related pneumonitis. DISCUSSION: The incidence of ethambutol-related toxic optic neuropathy has dramatically decreased since the recommendations for regular follow-up of patients treated with ethambutol. This treatment is classically responsible for bilateral central or ceco-central scotoma due to optic neuropathy, although a few cases of bitemporal hemianopia have been reported in the literature, mimicking a compressive chiasmal lesion. However, none of these cases demonstrated a hypersignal in the optic chiasm on brain magnetic resonance imaging (MRI).
CONCLUSION: Bitemporal hemianopia on visual field testing is very suggestive of a chiasmal lesion, which is generally due to a compressive, or more rarely inflammatory, lesion in the sellar region. Toxic chiasmal lesions are rare, but in the absence of any tumoral lesion in the sellar area, a detailed history must be obtained in order to rule out drug toxicity, so as to prevent irreversible visual loss.
Copyright © 2013. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Bitemporal hemianopia; Ethambutol; Hémianopsie bitemporale; Neuropathie optique; Optic neuropathy; Toxicity; Toxicité; Éthambutol

Mesh:

Substances:

Year:  2013        PMID: 24094504     DOI: 10.1016/j.jfo.2012.12.008

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  4 in total

Review 1.  Non-compressive disorders of the chiasm.

Authors:  Valerie A Purvin; Aki Kawasaki
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 5.081

2.  Ocular toxicity with ethambutol therapy: Timely recaution.

Authors:  Parvaiz A Koul
Journal:  Lung India       Date:  2015 Jan-Feb

3.  Campimetry and visual changes after RHZE treatment for tuberculosis.

Authors:  Brunella Maria Pavan Taffner; Luiz Guilherme Ito da Cruz; Flávio de Ávila Fowler; Carolynne Cardoso Nawa; Marcia Telma Savioli; Denise Silva Rodrigues; Octaviano Magalhães Junior; Rubens Belfort Junior
Journal:  Int J Retina Vitreous       Date:  2022-03-07

4.  Macular thickness as a predictor of loss of visual sensitivity in ethambutol-induced optic neuropathy.

Authors:  Chun-Xia Peng; Ai-di Zhang; Bing Chen; Bing-Jian Yang; Qiu-Hong Wang; Mo Yang; Shi-Hui Wei
Journal:  Neural Regen Res       Date:  2016-03       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.